BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical & Diagnostic

Aptamer Group Signs £465,000 Agreement for Development of Cervical Cancer Blood Test

Agreement for up to £465,000 signed for Optimer development Optimer binders will be developed for use in a cervical cance...

May 22, 2024 | News

RemeGen Announces Completion of Patient Enrollment for Two Phase III Clinical Trials of Telitacicept in China

RemeGen Co. a commercial-stage biotechnology company, recently announced significant progress of Telitacicept (RC18), that two Phase III clinical tria...

May 22, 2024 | News

AstraZeneca Announces $1.5 Billion Manufacturing Facility in Singapore for Cutting-Edge Cancer Treatments

AstraZeneca intends to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global s...

May 20, 2024 | News

Serum Institute of India Acquires 20% Stake in IntegriMedical to Accelerate Development of Needle-Free Injection Technology

- With this investment, SII will acquire 20% stake in IntegriMedical - ...

May 20, 2024 | News

Amplexd Therapeutics Secures $2 Million in Strategic Funding to Advance Non-Invasive Treatments for HPV-Induced Cervical Precancers

Amplexd Therapeutics, Inc. (“Amplexd” or the “Company”), a clinical stage patient-scientist-led biotech company specializing in acc...

May 20, 2024 | News

Amgen's IMDELLTRA™ Approved for Aggressive Lung Cancer

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the treatment of adult patients with e...

May 17, 2024 | News

A&D Invests $1M in Aevice Health to Expand Remote Respiratory Solutions

A&D Company, Limited has entered into a US$1M investment agreement with Aevice Health The collaboration is geared towards jointly expand...

May 15, 2024 | News

Arcellx and Kite Announce Phase 3 Trial for Anito-cel in Multiple Myeloma Patients

-- The companies share design of global Phase 3 trial, iMMagine-3; will evaluate anito-cel in patients exposed to both an immunomodulatory (lMi...

May 10, 2024 | News

Formosa Pharmaceuticals Strikes Exclusive Licensing Deal with Tabuk for Innovative Eye Surgery Drug in MENA

Taiwan-based Formosa Pharmaceuticals announced that the company has entered into an exclusive licensing agreement with Tabuk Pharmaceuticals Manufacturing ...

May 10, 2024 | News

GHIT Fund Allocates JPY 1.64 Billion to Combat Malaria and Neglected Tropical Diseases Through Innovative Partnerships

The Global Health Innovative Technology (GHIT) Fund announced a substantial investment of approximately JPY 1.64 billion (USD 10.8 million) dedicated...

May 09, 2024 | News

Sciwind Biosciences and HK inno.N Forge Partnership to Bring New Diabetes Treatment to South Korea

Sciwind Biosciences Co., Ltd., a clinical stage biopharmaceutical company focused on developing treatments for metabolic disease, and HK inno.N Corporation...

May 07, 2024 | News

FDA Approves Geneoscopy's Noninvasive Colorectal Cancer Test, ColoSense

Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, announced that the U...

May 07, 2024 | News

ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types

The agreement aims to supply ImmunityBio with Bacillus Calmette-Guerin (BCG), a critical component in cancer treatment. Under the collaboration, the ...

May 06, 2024 | News

HanAll Launches Phase III VELOS-4 Trial for Tanfanercept in Dry Eye Treatment

HanAll has initiated a Phase III VELOS-4 study to evaluate the efficacy and safety of tanfanercept in dry eye based on the findings from the previous Pha...

May 06, 2024 | News

Stay Connected